Hyman, David M <br/><br/>
A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.  [electronic resource] 

 -  Gynecologic oncology  Jan 2017 
 - 96-100 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>1095-6859 
<br/><br/><label>Standard No.: </label>10.1016/j.ygyno.2016.10.036  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--adverse effects<br/>Azepines--adverse effects<br/>Disease Progression<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Leiomyosarcoma--drug therapy<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Protein Kinase Inhibitors--therapeutic use<br/>Pyrimidines--adverse effects<br/>Response Evaluation Criteria in Solid Tumors<br/>Retreatment<br/>Survival Rate<br/>Uterine Neoplasms--drug therapy